Showing results (41-50 of 160) with videos related to
Sort By:
Pageof 16
Biochemical Pharmacology|December 11, 2002
Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acidShufeng Zhou, Philip Kestell, Bruce C Baguley, et al.International Journal of Pharmaceutics|October 14, 2008
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous deliverySrinivas Ganta, James W Paxton, Bruce C Baguley, et al.Journal of Pharmaceutical and Biomedical Analysis|November 6, 2007
Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatographySrinivas Ganta, James W Paxton, Bruce C Baguley, et al.Cancer Chemotherapy and Pharmacology|September 24, 2009
Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in micePradeep B Lukka, James W Paxton, Philip Kestell, et al.Pigment Cell & Melanoma Research|February 25, 2017
PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferationJillian M Silva, Marian M Deuker, Bruce C Baguley, et al.Investigational New Drugs|January 5, 2007
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Liangli Zhao, Elaine S Marshall, Lloyd R Kelland, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 18, 2008
Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049)Pradeep B Lukka, Philip Kestell, James W Paxton, et al.Frontiers in Genetics|June 12, 2013
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell linesJi Eun Kim, Euphemia Leung, Bruce C Baguley, et al.Journal of Theoretical Biology|July 4, 2009
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from themLiene Daukste, Britta Basse, Bruce C Baguley, et al.Cancer Chemotherapy and Pharmacology|June 5, 2012
Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokineticsPradeep B Lukka, James W Paxton, Philip Kestell, et al.Pageof 16